文献速递肾移植

肾移植受者首次检出新生供体特异性HLA抗体后移植物衰竭的预测因素

Predictors of graft failure after first detection of de novo donor-specific HLA antibodies in kidney transplant recipients.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

该回顾性研究纳入400例首次检出dnDSA的肾移植受者,中位随访8.3年,33.3%发生移植物衰竭。基线eGFR和蛋白尿与5年移植物丢失相关(AUC 0.75和0.80,P<.001),排斥反应是所有肾脏终点和移植物丢失最重要的独立危险因素。

要点

  • 基线eGFR和蛋白尿可预测dnDSA患者5年移植物丢失,AUC分别为0.75和0.80。
  • eGFR下降≥30%作为替代终点预测移植物丢失的PPV为45.9%。
  • 排斥反应是dnDSA患者所有肾脏终点和移植物丢失最重要的独立危险因素。

核心结论

  • 肾功能、蛋白尿和排斥反应与dnDSA患者移植物衰竭强相关,可能作为替代终点。

研究设计与样本

  • 回顾性研究,纳入2000年3月1日至2021年5月31日本中心400例首次检出dnDSA的肾移植受者。

主要发现

  • 随访8.3年期间,33.3%的患者发生移植物衰竭。
  • 基线eGFR和蛋白尿与5年移植物丢失相关,AUC分别为0.75和0.80(P<.001)。
  • 从dnDSA检出至肌酐翻倍的中位时间为2.8年(IQR 1.5-5.0),从肌酐翻倍至移植物衰竭的时间为1.0年(IQR 0.4-2.9)。
  • eGFR下降≥30%作为替代终点(148/400),从dnDSA至该事件的中位时间为2.0年(IQR 0.6-4.2),预测移植物丢失的PPV为45.9%,移植物丢失发生在2.0年后(IQR 0.8-3.2)。
  • 蛋白尿≥500 mg/g和≥1000 mg/g至移植物衰竭的中位时间均为1.8年,PPV分别为43.8%和49.0%;复合终点未提高PPV。

关键数值与推荐

  • 基线eGFR预测5年移植物丢失的AUC为0.75(P<.001)。
  • 基线蛋白尿预测5年移植物丢失的AUC为0.80(P<.001)。
  • eGFR下降≥30%预测移植物丢失的PPV为45.9%。
  • 蛋白尿≥500 mg/g预测移植物丢失的PPV为43.8%;蛋白尿≥1000 mg/g预测移植物丢失的PPV为49.0%。

临床怎么用

  • 在无症状dnDSA患者中,基线eGFR和蛋白尿可用于预测5年移植物丢失风险。
  • eGFR下降≥30%、蛋白尿≥500 mg/g或≥1000 mg/g可作为候选替代终点用于临床监测。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: De novo donor-specific antibodies (dnDSAs) may cause antibody-mediated rejection and graft dysfunction. Little is known about the clinical course after first detection of dnDSAs during screening in asymptomatic patients. We aimed to assess the value of estimated glomerular filtration rate (eGFR) and proteinuria to predict graft failure in patients with dnDSAs and their potential utility as surrogate endpoints. METHODS: All 400 kidney transplant recipients with dnDSAs at our centre (1 March 2000-31 May 2021) were included in this retrospective study. The dates of graft loss, rejection, doubling of creatinine, ≥30% eGFR decline, proteinuria ≥500 mg/g and ≥1000 mg/g were registered from the first dnDSA appearance. RESULTS: During 8.3 years of follow-up, graft failure occurred in 33.3% of patients. Baseline eGFR and proteinuria correlated with 5-year graft loss (area under the receiver operating characteristics curve 0.75 and 0.80, P < .001). Creatinine doubled after a median of 2.8 years [interquartile range (IQR) 1.5-5.0] from dnDSA and the time from doubling creatinine to graft failure was 1.0 year (IQR 0.4-2.9). Analysing eGFR reduction ≥30% as a surrogate endpoint (148/400), the time from dnDSA to this event was 2.0 years (IQR 0.6-4.2), with a positive predictive value (PPV) of 45.9% to predict graft loss, which occurred after 2.0 years (IQR 0.8-3.2). The median time from proteinuria ≥500 mg/g and ≥1000 mg/g to graft failure was identical, 1.8 years, with a PPV of 43.8% and 49.0%, respectively. Composite endpoints did not improve PPV. Multivariable analysis showed that rejection was the most important independent risk factor for all renal endpoints and graft loss. CONCLUSIONS: Renal function, proteinuria and rejection are strongly associated with graft failure in patients with dnDSA and may serve as surrogate endpoints.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. López Del Moral C, Wu K, Naik M, et al. Predictors of graft failure after first detection of de novo donor-specific HLA antibodies in kidney transplant recipients. Nephrol Dial Transplant. 2023. PMID: 37410616. doi:10.1093/ndt/gfad149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。